References
- CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer–preliminary analysis. Br J Cancer 1988; 51: 604–7
- Houghton J, Baum M, Nissen-Meyer R, Riley D A, Hern R. Is there a role for perioperative adjuvant cytotoxic therapy in the treatment of early breast cancer?. Recent Results Cancer Res 1989; 115: 54–61
- Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2: 282, letter
- Early Breast Cancer Trialists Collaborative Group. Treatment of early breast cancer, Vol 1. Worldwide evidence 1985–1990. Oxford University Press, Oxford 1990
- Nolvadex Adjuvant Trial Organisation (NATO). Controlled trial of tamoxifen as a single agent in the management of early breast cancer–analysis at eight years. Br J Cancer 1988; 57: 608–11
- A'Hern R, Baum M, Dowsett M. How does tamoxifen interact with chemotherapy?. Lancet 1991; 337: 439–40
- Baum M. Prospects for the future in the management of carcinoma of the breast: The ‘biological fall out’ from clinical trials. Adjuvant therapy of cancer IV, S E Jones, S E Salmon. Grune and Stratton. 1984; 321–9
- Jordan V C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976; 12: 419–24